Cargando…

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

INTRODUCTION: Protein C, because of its central role in hemostasis, plays an integral role in the host response to infection. Protein C depletion, resulting from increased consumption, degradation, and/or decreased synthesis, is characteristic of sepsis and has been shown to predict morbidity and mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shorr, Andrew F, Bernard, Gordon R, Dhainaut, Jean-Francois, Russell, James R, Macias, William L, Nelson, David R, Sundin, David P
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550956/ https://www.ncbi.nlm.nih.gov/pubmed/16780598 http://dx.doi.org/10.1186/cc4946

Ejemplares similares

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis
por: Laterre, Pierre-François, et al.
Publicado: (2008)

Diagnosis and treatment of severe sepsis
por: Claessens, Yann-Erick, et al.
Publicado: (2007)

Re-establishing organ function in severe sepsis: targeting the microcirculation
por: Dhainaut, Jean-François
Publicado: (2005)

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Beale, R, et al.
Publicado: (2004)

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
por: Macias, William L, et al.
Publicado: (2005)

Soluble ST2 plasma concentrations predict mortality in severe sepsis
por: Hoogerwerf, Jacobien J., et al.
Publicado: (2010)

Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis
por: Dhainaut, Jean-François
Publicado: (2009)

The Immune Response: Targets for the Treatment of Severe Sepsis
por: Bernard, Aline M., et al.
Publicado: (2012)

Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
por: Shorr, Andrew F, et al.
Publicado: (2008)

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]
por: Kinasewitz, Gary T, et al.
Publicado: (2004)

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock
por: Taccone, Fabio Silvio, et al.
Publicado: (2010)

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE
por: Vincent, J, et al.
Publicado: (2004)

Drotrecogin alfa (activated) in the subgroup of patients with multiple organ dysfunction (MOD) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
por: Vincent, J, et al.
Publicado: (2004)

Plasma procalcitonin concentrations are increased in dogs with sepsis
por: Goggs, Robert, et al.
Publicado: (2018)

Low plasma citrulline levels are associated with acute respiratory distress syndrome in patients with severe sepsis
por: Ware, Lorraine B, et al.
Publicado: (2013)

Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients
por: Wang, HaiHong, et al.
Publicado: (2008)

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
por: Dellinger, R. Phillip, et al.
Publicado: (2007)

Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
por: Dellinger, R. Phillip, et al.
Publicado: (2008)

Delayed ICU admission with community-acquired severe sepsis greatly increases mortality and resource use
por: Shorr, A, et al.
Publicado: (2011)

Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients
por: Wort, S, et al.
Publicado: (2004)

Early exposure to hyperoxia and mortality in critically ill patients with severe traumatic injuries
por: Russell, Derek W., et al.
Publicado: (2017)

Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients
por: Rhodes, Andrew, et al.
Publicado: (2006)

Prognostic utility of plasma lactate measured between 24 and 48 h after initiation of early goal-directed therapy in the management of sepsis, severe sepsis, and septic shock
por: Chertoff, Jason, et al.
Publicado: (2016)

Reducing mortality in sepsis: new directions
por: Vincent, Jean-Louis, et al.
Publicado: (2002)

Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis and septic shock
por: Brunkhorst, FM, et al.
Publicado: (1999)

“Early goal-directed therapy” versus “Early” and “goal-directed” therapy for severe sepsis and septic shock: Time to rationalize
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Increased plasma vaspin concentration in patients with sepsis: an exploratory examination
por: Motal, Michael C., et al.
Publicado: (2015)

Vitamin D deficiency and risk of acute lung injury in severe sepsis and severe trauma: a case-control study
por: Barnett, Nicolas, et al.
Publicado: (2014)

Clusterin Plasma Concentrations Are Decreased in Sepsis and Inversely Correlated with Established Markers of Inflammation
por: Yagmur, Eray, et al.
Publicado: (2022)

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009)

Hyperuricemia: An Early Marker for Severity of Illness in Sepsis
por: Akbar, Sana R., et al.
Publicado: (2015)

Cost-effectiveness of early goal-directed therapy in the treatment of severe sepsis and septic shock
por: Huang, DT, et al.
Publicado: (2003)

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with an APACHE II score of 25 or greater at baseline: results from ENHANCE
por: Doig, C, et al.
Publicado: (2004)

Plasma procalcitonin concentrations predict organ dysfunction and outcome in dogs with sepsis
por: Troia, Roberta, et al.
Publicado: (2018)

Direct intensive care costs of severe sepsis and septic shock patients in Thailand
por: Khwannimit, B, et al.
Publicado: (2015)

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Vincent, Jean-Louis, et al.
Publicado: (2006)

Lactate quartile concentration and prognosis in severe sepsis and septic shock
por: De La Torre-Prados, M, et al.
Publicado: (2014)

Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome
por: Ware, Lorraine B, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h636gmjnrfju6aqudsquomhq68